CA-XSOLLA
14.3.2024 15:22:26 CET | Business Wire | Press release
Xsolla, a global video game commerce company, announces its partnership with GameAnalytics, a premier analytics platform in the gaming industry. This partnership marks the beginning of a new era of in-game monetization, with the integration of Xsolla's Web Shop into the GameAnalytics platform. The initiative aims to provide game developers with next-generation tools for direct-to-consumer sales, starting with a pioneering proof of concept centered around the Xsolla Web Shop.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314598476/en/
(Graphic: Xsolla)
"This partnership with GameAnalytics is a game-changer for developers worldwide. Combining GameAnalytics' powerful data analysis tools with Xsolla's comprehensive sales solutions provides developers with an unprecedented opportunity to understand and engage their audience directly," said Berkley Egenes, Chief Marketing Officer and Chief Growth Officer at Xsolla. "This empowers developers to maximize their revenue potential and enhances the gaming experience for players by ensuring the games they love continue to thrive."
Game developers integrate their games with GameAnalytics to access mission-critical data and uncover valuable insights about their games’ performance, including engagement and monetization data. This, above others, allows them to understand player spending behavior, optimize their revenue streams, and maximize earning potential.
"We are excited to embark on this partnership with Xsolla, a company that shares our commitment to empowering game developers," said Allison Bilas, COO at GameAnalytics. “Integrating Xsolla's Web Shop into our analytics platform opens new avenues for developers to monetize their games more effectively. This collaboration is about providing actionable insights that enable developers to craft compelling experiences for gamers while optimizing their revenue streams. It's a testament to our shared vision of supporting the growth and success of the gaming community."
Xsolla is a pivotal player in the gaming industry, collaborating with thousands of developers, publishers, and platforms, including Epic Games, Roblox, Twitch, Steam, Kabam, Niantic, EA, Warner Brothers, Wizards of the Coast, Sega, Take Two, SciPlay and Miniclip. As a merchant of record, Xsolla undertakes the risk and operational complexity associated with direct-to-consumer video game sales, addressing challenges such as chargebacks, fraud, taxes, and compliance laws. This partnership underscores Xsolla's commitment to supporting the gaming community by facilitating direct sales to consumers online, bypassing substantial platform fees associated with traditional app stores.
With the recent announcement of powering web shops for 40 of the top 100 mobile games, Xsolla continues demonstrating its dedication to innovation and support for mobile game developers. The collaboration with GameAnalytics represents a significant step forward in achieving this goal, offering developers cutting-edge tools to analyze, understand, and monetize their games effectively.
For more information about the partnership, please visit: https://xsolla.pro/xsolla-gameanalytics
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
About GameAnalytics
GameAnalytics is the leading analytics solution for indie developers, game studios, and powerhouse publishers globally. Their network covers 100,000 games played by over 1.75 billion people for an average of 24 billion monthly sessions. The GameAnalytics platform enables game development teams to rapidly refine gameplay, improve retention, and increase revenue with real-time data analysis for all major game engines and operating systems through simple SDK integration. GameAnalytics was founded in 2012 by Danish serial entrepreneur Morten E. Wulff, who remains the company's Chairman today. After raising over $8M in funding, the leading mobile advertising company, Mobvista, acquired the company in 2016. To learn more and get started for free, visit gameanalytics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314598476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom